Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Short interferon and riba… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience

Artikel i vetenskaplig tidskrift
Författare Jesper Waldenström
M. Farkkila
Karolina Rembeck
Gunnar Norkrans
N. Langeland
K. Morch
C. Pedersen
M. Rauning Buhl
U. Nieminen
H. Nuutinen
Åsa Alsiö
L. Holmstrom
R. Jungnelius
K. Lund
A. Rubensson
E. Torell
Johan Westin
Martin Lagging
Publicerad i Scandinavian Journal of Gastroenterology
Volym 51
Nummer/häfte 3
Sidor 337-343
ISSN 0036-5521
Publiceringsår 2016
Publicerad vid Institutionen för biomedicin, avdelningen för infektionssjukdomar
Sidor 337-343
Språk en
Länkar dx.doi.org/10.3109/00365521.2015.10...
Ämnesord genotype 2, genotype 3, hepatitis C virus, inosine triphosphate pyrophosphatase, interferon, ITPA, chronic hepatitis-c, triphosphate pyrophosphohydrolase deficiency, genetic-basis, sofosbuvir, therapy, population, variants, anemia, Gastroenterology & Hepatology
Ämneskategorier Endokrinologi och diabetes, Invärtesmedicin

Sammanfattning

Objective: Interferon-free therapy for hepatitis C virus (HCV) infection is costly, and therefore patients with advanced fibrosis are prioritized. Although coupled with considerable side effects, a large proportion of genotype 2/3 infected patients achieve a sustained virological response (SVR) following interferon-based therapy. The present study evaluates experimental clinical trial and verifying real-life data with the aim of identifying patients with a high likelihood of favorable outcome following short interferon-based treatment. Material and methods: The impact of established response predictors, e.g. age, ITPA and IL28B genetic variants, IP-10, liver histopathology and early viral kinetics on outcome was evaluated among HCV genotype 2/3 infected patients enrolled in the NORDynamIC trial. Similarly outcome was evaluated among Finnish and Swedish real-life genotype 2/3 infected patients treated for 12-16 weeks in accordance with national guidelines. Results: In the NORDynamIC trial, age <40 years or achieving HCV RNA<1000 IU/mL day 7 were highly predictive of favorable outcome following 12 weeks therapy. Among 255 Finnish real-life patients below the age of 40 years treated for 12 weeks with interferon and ribavirin, 87% of HCV genotype 2 and 79% of genotype 3 infected patients achieved SVR, and among 117 Swedish real-life patients treated for 12-16 weeks, 97% of HCV genotype 2 and 94% of genotype 3 infected achieved SVR. Conclusions: Short interferon-based therapy offers a high likelihood of achieving SVR for selected HCV genotype 2/3 infected patients, and is an acceptable option given that a thorough discussion of the side effects is provided prior to initiation.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?

Denna text är utskriven från följande webbsida:
http://www.gu.se/forskning/publikation/?publicationId=228133
Utskriftsdatum: 2019-09-21